December 13, 2021 09:00 AM EST
FDA+
Coronavirus

Genen­tech's tocilizum­ab short­age due to Covid-19 now hits CAR-T re­cip­i­ents, with FDA of­fer­ing al­ter­na­tives to help

Zachary Brennan

Senior Editor

Soon af­ter San Fran­cis­co-based Genen­tech won an EUA for tocilizum­ab as a treat­ment for hos­pi­tal­ized Covid pa­tients last sum­mer, the com­pa­ny an­nounced a short­age of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times